188 related articles for article (PubMed ID: 33382729)
41. Mucosal-associated invariant T cell alterations during the development of human type 1 diabetes.
Gazali AM; Schroderus AM; Näntö-Salonen K; Rintamäki R; Pihlajamäki J; Knip M; Veijola R; Toppari J; Ilonen J; Kinnunen T
Diabetologia; 2020 Nov; 63(11):2396-2409. PubMed ID: 32880687
[TBL] [Abstract][Full Text] [Related]
42. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
43. Mucosal-Associated Invariant T Cells Are More Activated in Chronic Hepatitis B, but Not Depleted in Blood: Reversal by Antiviral Therapy.
Boeijen LL; Montanari NR; de Groen RA; van Oord GW; van der Heide-Mulder M; de Knegt RJ; Boonstra A
J Infect Dis; 2017 Nov; 216(8):969-976. PubMed ID: 28968772
[TBL] [Abstract][Full Text] [Related]
44. Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection.
Macías J; Granados R; Téllez F; Merino D; Pérez M; Morano LE; Palacios R; Paniagua M; Frías M; Merchante N; Pineda JA;
J Viral Hepat; 2019 Jan; 26(1):16-24. PubMed ID: 30141222
[TBL] [Abstract][Full Text] [Related]
45. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
Capa L; Soriano V; García-Samaniego J; Nuñez M; Romero M; de Mendoza C; Cascajero A; Muñoz F; González-Lahoz J; Benito JM
Antivir Ther; 2007; 12(4):459-68. PubMed ID: 17668554
[TBL] [Abstract][Full Text] [Related]
46. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
[TBL] [Abstract][Full Text] [Related]
47. Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.
Behzadpour D; Ahmadi Vasmehjani A; Mousavi Nasab SD; Ahmadi NA; Baharlou R
Pathog Glob Health; 2016; 110(7-8):310-315. PubMed ID: 27830997
[TBL] [Abstract][Full Text] [Related]
48. Successful direct-acting antiviral therapy in HIV/HCV co-infected patients fails to restore circulating mucosal-associated invariant T cells.
Cannizzo ES; Cerrone M; Merlini E; van Wilgenburg B; Swadling L; Ancona G; De Bona A; d'Arminio Monforte A; Klenerman P; Marchetti G
Eur J Immunol; 2019 Jul; 49(7):1127-1129. PubMed ID: 30985000
[No Abstract] [Full Text] [Related]
49. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
[TBL] [Abstract][Full Text] [Related]
50. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
[TBL] [Abstract][Full Text] [Related]
51. Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV coinfection.
Barrett L; Gallant M; Howley C; Ian Bowmer M; Hirsch G; Peltekian K; Grant M
J Viral Hepat; 2011 Mar; 18(3):170-80. PubMed ID: 20497309
[TBL] [Abstract][Full Text] [Related]
52. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
Ingiliz P; Christensen S; Kimhofer T; Hueppe D; Lutz T; Schewe K; Busch H; Schmutz G; Wehmeyer MH; Boesecke C; Simon KG; Berger F; Rockstroh JK; Schulze zur Wiesch J; Baumgarten A; Mauss S
Clin Infect Dis; 2016 Nov; 63(10):1320-1324. PubMed ID: 27535952
[TBL] [Abstract][Full Text] [Related]
53. Management and treatment of chronic hepatitis C in HIV patients.
Barreiro P; Vispo E; Labarga P; Soriano V
Semin Liver Dis; 2012 May; 32(2):138-46. PubMed ID: 22760653
[TBL] [Abstract][Full Text] [Related]
54. Association Between Impaired Vα7.2+CD161++CD8+ (MAIT) and Vα7.2+CD161-CD8+ T-Cell Populations and Gut Dysbiosis in Chronically HIV- and/or HCV-Infected Patients.
Merlini E; Cerrone M; van Wilgenburg B; Swadling L; Cannizzo ES; d'Arminio Monforte A; Klenerman P; Marchetti G
Front Microbiol; 2019; 10():1972. PubMed ID: 31555223
[TBL] [Abstract][Full Text] [Related]
55. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
[TBL] [Abstract][Full Text] [Related]
56. DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV.
El-Garem H; AbdAllah M; Omar H; Cordie A; Abdel Alem S; Mohey Eldin Elzahry MA; Ghaith D; Abou El-Soud NH; Kamal W; Elsharkawy A; Esmat G
Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):693-698. PubMed ID: 31043104
[No Abstract] [Full Text] [Related]
57. Chronic Viral Infection Compromises the Quality of Circulating Mucosal-Associated Invariant T Cells and Follicular T Helper Cells via Expression of Inhibitory Receptors.
Vimali J; Yong YK; Murugesan A; Tan HY; Zhang Y; Ashwin R; Raju S; Balakrishnan P; Larsson M; Velu V; Shankar EM
Front Biosci (Landmark Ed); 2024 Mar; 29(3):128. PubMed ID: 38538288
[TBL] [Abstract][Full Text] [Related]
58. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.
Fouad R; Elsharkawy A; Abdel Alem S; El Kassas M; Alboraie M; Sweedy A; Afify S; Abdellatif Z; Khairy M; Esmat G
Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1129-1134. PubMed ID: 30896550
[TBL] [Abstract][Full Text] [Related]
59. Lasting differential gene expression of circulating CD8 T cells in chronic HCV infection with cirrhosis identifies a role for Hedgehog signaling in cellular hyperfunction.
Li J; Vranjkovic A; Read D; Delaney SP; Stanford WL; Cooper CL; Crawley AM
Front Immunol; 2024; 15():1375485. PubMed ID: 38887299
[TBL] [Abstract][Full Text] [Related]
60. Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects.
Zuccalà P; Latronico T; Marocco R; Savinelli S; Vita S; Mengoni F; Tieghi T; Borgo C; Kertusha B; Carraro A; D'Ettorre G; Vullo V; Mastroianni CM; Liuzzi GM; Lichtner M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
